Plaque Psoriasis

Patients with psoriasis in high-impact areas may benefit from either of 2 available dosing regimens of the biologic.

Despite a Boxed Warning included in its 2017 FDA approval, the plaque psoriasis biologic was not linked to any causal cases of suicide attempts in 4-year, real-world data.

New trial data presented at ACAAI 2022 suggest a potential insight into treating chronic spontaneous urticaria after a period of omalizumab treatment.

An online survey of adult patients shows a strong desire for a singular, consistent topical option.

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

New registry analysis shows persistent treatment with the IL-23 improved disease in patients predominately with a history of past biologic therapies.

Researchers tested the newly-designed Rosacea Area and Severity Index, or RASI, against the Investigator’s Global Assessment tool used to assess rosacea concerns for patients.

In a recent study, patients with plaque psoriasis or vitiligo who were receiving phototherapy were found to have higher rates of skin cancer than the general population.

New research suggests that certain interleukin-17 blockage therapies may not alleviate sleeping issues in patients with psoriasis.

A recent discussion with Dr. Brown on the use of tapinarof, approved for adult plaque psoriasis, in patients with atopic dermatitis.

Recent clinical trial data from UNCOVER-1 and UNCOVER-2 demonstrated the positive effects of ixekizumab use in adult plaque psoriasis patients.

The recent GUIDE study examined the efficacy of guselkumab for moderate-to-severe plaque psoriasis, finding it consistent with previous trials.

The moisturizer was designed to address concerns regarding the suitability of sunscreens for individuals with skin of color and show the importance of "aesthetic elegance” to increase sunscreen utilization.

Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.

A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.

PASI 100 was achieved by 28% of patients in week 4, 89% in week 12, and 68% in week 36.

An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.

Overall, secukinumab was more effective in biologic-naïve patients and in patients with a lower body mass index (BMI).

A research team described data regarding the potential of escalating adalimumab doses for certain patients with psoriasis.

A combination therapy approach may be useful for psoriasis treatment, though an 8-week regimen may not be long enough.

Research suggests that tildrakizumab may be useful in real-life settings against moderate-to-severe plaque psoriasis.

Research finds potential benefits to using apremilast for plaque psoriasis patients.

The results of two phase 3 clinical trials suggest a topical psoriasis treatment option.

The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.

Recent research from the National Psoriasis Foundation (NPF) found that 1 in 3 individuals living with psoriatic conditions experience depression.